{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"100"},{"groupId":"OG002","value":"75"},{"groupId":"OG003","value":"100"},{"groupId":"OG004","value":"83.3"},{"groupId":"OG005","value":"100"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"3"}],"units":"Participants"}],"description":"Adverse event severity graded according to NCI CTCAE v5.0","groups":[{"description":"Participants in Arm A received 60 mg dose of RO7297089 as a flat dose at each scheduled study drug administration visit","id":"OG000","title":"Dose Escalation Cohort 1: RO7297089"},{"description":"Participants in Arm A received 180 mg dose of RO7297089 as a flat dose at each scheduled study drug administration visit","id":"OG001","title":"Dose Escalation Cohort 2: RO7297089"},{"description":"Participants in Arm A received 360 mg dose of RO7297089 as a flat dose at each scheduled study drug administration visit","id":"OG002","title":"Dose Escalation Cohort 3: RO7297089"},{"description":"Participants in Arm A received 1080 mg dose of RO7297089 as a flat dose at each scheduled study drug administration visit","id":"OG003","title":"Dose Escalation Cohort 4: RO7297089"},{"description":"Participants in Arm B received the 1080 mg dose of RO7297089 as a split dose divided over two days (Days 1 and 2). The full target dose wasadministered at subsequent study drug administration visits.","id":"OG004","title":"Dose Escalation Backfill Cohort 4: RO7297089"},{"description":"Participants in Arm B received the 1850 mg dose of RO7297089 as a split dose divided over two days (Days 1 and 2). The full target dose was administered at subsequent study drug administration visits.","id":"OG005","title":"Dose Escalation Cohort 5: RO7297089"}],"paramType":"NUMBER","populationDescription":"Safety-Evaluable Patients","reportingStatus":"POSTED","timeFrame":"Baseline up to 1 year 7 months","title":"Percentage of Participants With Adverse Events (AEs), Including Dose Limiting Toxicities (DLTs)","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}